- The proposed acquisition reinforces Navamedic's position in the
market for obesity treatment
- The acquired portfolio enables Navamedic to support patients
and consumers during weight loss or obesity treatment
- This agreement supports Navamedic's ambition to become a
leading Nordic provider of specialized, high-quality products to
hospitals and pharmacies
OSLO,
Norway, May 5, 2022 /PRNewswire/ -- Navamedic
ASA (OSE: NAVA), a Nordic pharma company and reliable provider of
high-quality products to hospitals and pharmacies, and Impolin AB
(Impolin), a Swedish-based, independent distributor of products
that benefit the health and wellbeing of consumers and patients,
today announce that Navamedic will acquire Impolin to expand its
product portfolio for obesity treatment.
Impolin's portfolio includes Modifast, a range of diet and meal
replacement products, and MedMade, a multivitamin and minerals
tablet for post-bariatric surgery supplementation, which are
products aimed at supporting patients during weight loss or obesity
treatment, including bariatric surgery. Impolin's third product is
Absolut Torr/Absolute Dry, extra effective antiperspirants
primarily for hyperhidrosis, excessive sweating.
The addition of Modifast and MedMade is set to broaden
Navamedic's current product offering within the area of obesity
treatment and enables Navamedic to support patients throughout the
entire weight loss journey.
Obesity is considered a disease that increases the likelihood of
various other diseases and conditions, such as type 2 diabetes and
cardiovascular disease. Between 15-and 20%[1] of people
in the Nordic population are considered obese, whereby the cost of
treatment and related complications are increasing. Weight loss
remains the key in the management of obesity and is often a
prerequisite for patients seeking to undergo bariatric surgery.
"The world has seen obesity nearly triple since 1975, making it
a significant public health concern. Navamedic has been ramping up
activities in this important segment and is now in an ideal
position to improve the product offering for patients and consumers
seeking to undergo weight loss in a safe and effective way.
"Our ambitions are bold, but by capitalizing on the strong
transaction synergies, I am confident that we will successfully
launch our expanded product range across the Nordic territory.
Together with the Impolin team, we are planning to launch Modifast
in Norway in 2023, followed by
rollout in Finland and
Denmark, and double product
revenue by the end of 2028," commented Kathrine Gamborg Andreassen, CEO of
Navamedic.
"Navamedic has dedicated part of its product portfolio to
treating obesity, making the company our preferred partner. With
Navamedic's position as a reliable supplier of high-quality
products in the Nordics, we believe this agreement will accelerate
access to our products for patients outside of Sweden. I look forward to collaborating
closely with the team at Navamedic to contribute to improving the
quality of life for people," said Tony Brejke, Managing Director
and owner of Impolin AB.
For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars
Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail:
lars.hjarrand@navamedic.com
About Navamedic
Navamedic ASA is a full-service provider of high-quality
healthcare products to hospitals and pharmacies. Navamedic meets
the specific medical needs of patients and consumers by leveraging
its highly scalable market access platform, leading category
competence and local knowledge. Navamedic is present in all the
Nordic countries, the Baltics and Benelux, with sales
representation in the UK and Greece. Navamedic is headquartered in
Oslo, Norway, and listed on the
Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com
About Impolin AB
Impolin AB (Impolin) is a Swedish-based, independent distributor
of products that benefit the health and wellbeing of consumers and
patients. The portfolio includes own brands as well as
international distribution agreements. Pharmacies are the sole
distribution channel, alongside the branded website with e-trade.
The company also exports Absolut Torr, to other countries and
regions, via third party distributors. For more information, please
visit www.impolin.com
[1] World Obesity. Global Obesity Observatory
https://data.worldobesity.org/.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/navamedic-asa/r/navamedic-asa-acquires-impolin-ab-and-bolsters-its-product-portfolio,c3561105